BioWorld

Nov. 18, 2010

Roche Steps Back from RNA Interference, Cuts 6% of Staff

As part of a cost-cutting corporate restructuring, Roche AG plans to discontinue its preclinical research in the area of RNA interference (RNAi) at sites in Kulmbach, Germany; Madison, Wisc.; and Nutley, N.J. (BioWorld Today) Read More

Avanir Raising $88M Post-Nuedexta Approval

From 'FAB' to Flush: Sutro Adding $36.5M in Series C

Investors Hammer Resverlogix Over Cholesterol Drug Data

Forma Will Get $20M from Eisai in Drug Discovery Deal

Clinic Roundup

Stock Movers

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

GLP-1s need technologies for long-term use

BioWorld

For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...

UTRN gene involved in arthrogryposis, study finds

BioWorld Science

Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...

mRNA vaccines are composed of messenger RNA encapsulated in lipid nanoparticles

mRNA flu vaccine can activate broad germinal center response

BioWorld

On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...